Cialis vs. Alprostadil (Caverject/MUSE): Switching Between Them

How Each Drug Produces an Erection

Tadalafil and alprostadil reach the same endpoint through unrelated biochemical pathways, which is precisely why switching or even combining them is pharmacologically viable.

Tadalafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in penile smooth muscle. By blocking PDE5, tadalafil prolongs the nitric-oxide-driven cGMP signal that relaxes the corpus cavernosum and permits blood inflow 1. Its half-life of 17.5 hours gives it a 36-hour window of effectiveness, a feature that distinguishes it from shorter-acting PDE5 inhibitors 2. The FDA label permits both on-demand dosing (10 to 20 mg) and daily use (2.5 to 5 mg) for ED, with the daily regimen also approved for benign prostatic hyperplasia (BPH) symptoms 3.

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP receptors on cavernosal smooth muscle cells, activating adenylate cyclase and raising intracellular cyclic adenosine monophosphate (cAMP) 4. This cAMP pathway relaxes smooth muscle independently of nitric oxide, meaning alprostadil works even when endothelial function is severely compromised. The Caverject FDA label approves intracavernosal injection at 1 to 40 mcg, while MUSE delivers 125 to 1,000 mcg as a urethral pellet. Because the mechanism bypasses PDE5 entirely, alprostadil remains effective in men whose oral therapy has failed.

Efficacy Compared Across Trials

No head-to-head randomized trial has directly compared tadalafil to alprostadil. The evidence base consists of separate key studies, each conducted against placebo.

Brock et al. (2002) randomized 1,112 men with ED to tadalafil 10 mg, 20 mg, or placebo on demand. At 12 weeks, 81% of men on 20 mg reported improved erections on the Global Assessment Question, compared to 35% on placebo 1. The mean per-patient success rate for intercourse attempts (SEP3) was 75% at 20 mg versus 32% for placebo. Tadalafil maintained efficacy for up to 36 hours post-dose 2.

Linet and Ogrinc (1996) studied intracavernosal alprostadil in 296 men. Adequate erections for intercourse occurred in approximately 70% of injections across varied etiologies, and response rates exceeded 65% even in the subgroup with vasculogenic ED 4. A separate meta-analysis confirmed alprostadil injection response rates of 72 to 87% across 48 trials, making it the most reliably effective monotherapy for refractory ED 5.

For the MUSE formulation, Padma-Nathan et al. (1997) enrolled 1,511 men and found a 65.9% in-clinic response rate; at-home efficacy dropped to 50.4% over three months, reflecting the lower bioavailability of the urethral route 6. MUSE is therefore considered less potent than injection but more acceptable to patients who refuse self-injection.

The AUA guideline on ED (2018, amended 2023) positions oral PDE5 inhibitors as first-line pharmacotherapy and alprostadil injection or MUSE as second-line options for men who fail, cannot tolerate, or have contraindications to oral agents 7.

When Switching from Tadalafil to Alprostadil Makes Sense

About 30 to 35% of men do not respond adequately to PDE5 inhibitors, a figure that rises sharply in populations with diabetes, post-prostatectomy nerve damage, or severe vascular disease 8.

Switching to alprostadil is indicated in several clinical scenarios. The first is true PDE5 inhibitor failure, defined as no adequate erection after at least four to six properly timed attempts at the maximum tolerated dose 7. The second is a contraindication to PDE5 inhibitors: men taking nitrate medications for angina cannot use any PDE5 inhibitor because of the risk of severe hypotension 9. Tadalafil is also contraindicated with certain alpha-blockers and potent CYP3A4 inhibitors at higher doses 3.

Post-radical prostatectomy ED represents a third common scenario. A 2005 study by Montorsi et al. Showed that early penile rehabilitation with intracavernosal alprostadil after nerve-sparing prostatectomy improved natural erection recovery at 12 months compared to observation alone 10. In these men, alprostadil injection may serve as a bridge therapy until nerve function recovers enough for oral agents to work.

The transition itself is simple. Tadalafil can be discontinued without tapering. At the next planned sexual encounter, the patient uses alprostadil instead. The AUA guideline does not require a washout interval between drug classes, because PDE5 inhibitors and prostaglandins act on independent signaling cascades 7.

When Switching from Alprostadil Back to Tadalafil Is Appropriate

Some men begin treatment on alprostadil, often after a radical prostatectomy or because of severe diabetes-related ED, and later become candidates for oral therapy.

Nerve regeneration after prostatectomy may take 12 to 24 months. As cavernosal nerve function recovers, a trial of tadalafil 5 mg daily can be introduced while tapering injection frequency 10. Mulhall et al. (2005) found that daily PDE5 inhibitor use after prostatectomy improved IIEF scores significantly compared to on-demand use alone, suggesting that the daily regimen optimizes endothelial recovery 11.

Men who started on alprostadil due to nitrate use may also become eligible for tadalafil if their cardiologist discontinues nitrates or switches to a non-nitrate antianginal regimen. The ACC/AHA consensus recommends waiting at least 48 hours after the last tadalafil dose before administering any nitrate (and vice versa), reflecting the drug's long half-life 12. That same 48-hour buffer applies when switching from nitrate therapy to a tadalafil-eligible cardiac regimen.

Injection-site complications provide another reason for switching. Penile fibrosis occurs in 2 to 12% of men using intracavernosal alprostadil long-term, and the MUSE urethral pellet causes penile pain in roughly 33% of users 6. For a man who develops a palpable plaque or persistent urethral burning, moving to oral tadalafil (if pharmacologically feasible) eliminates local trauma entirely.

Dose Titration Protocol for Each Direction

Switching requires careful dose finding because there is no cross-class dose equivalence table.

Tadalafil to Caverject injection: The initial test dose of alprostadil should be administered in the physician's office. The Caverject label recommends starting at 2.5 mcg for neurogenic ED or 10 mcg for vasculogenic/mixed ED, with increases of 2.5 to 5 mcg per visit until a rigid erection lasting no longer than 60 minutes is achieved 13. The maximum recommended dose is 40 mcg. Office titration is mandatory to screen for prolonged erection and identify the minimum effective dose.

Tadalafil to MUSE: Begin with the 250 mcg pellet in-office. Increase stepwise to 500 mcg or 1,000 mcg based on response. An optional constriction band at the penile base improves MUSE efficacy by 20 to 30% by slowing venous drainage 6.

Alprostadil to tadalafil: Start with tadalafil 10 mg on demand, taken at least 30 minutes before anticipated activity. If response is partial, increase to 20 mg. For men who prefer spontaneity or also have lower urinary tract symptoms, switch to tadalafil 5 mg daily after two to four weeks of on-demand use to confirm tolerability 3.

Combination Therapy: Tadalafil Plus Alprostadil

Rather than a clean switch, some clinicians prescribe both drugs concurrently. A randomized study by McMahon et al. (2006) enrolled PDE5-inhibitor partial responders and found that adding low-dose intracavernosal alprostadil (5 to 10 mcg) to sildenafil 100 mg improved erection rigidity in 89% of men compared to 31% with sildenafil alone 14. Although that trial used sildenafil, the principle extends to tadalafil given the shared PDE5 class mechanism.

The risk is synergistic hypotension and priapism. A 2011 review by Porst et al. Confirmed that combination therapy requires dose reduction of both agents and close initial monitoring 15. Patients must understand that if an erection lasts beyond four hours, they need emergency aspiration and phenylephrine injection to prevent ischemic corporal damage 7.

The EAU guidelines (2023) note that PDE5 inhibitor plus intracavernosal injection combination is a recognized salvage strategy before considering penile prosthesis implantation 16.

Safety, Side Effects, and Monitoring

Each drug carries a distinct adverse-event profile, and the differences often influence switching decisions.

Tadalafil's most common side effects are headache (14.5%), dyspepsia (12.3%), back pain (6.5%), myalgia (5.7%), and nasal congestion (4.3%) 1. The back pain and myalgia, caused by PDE11 cross-inhibition, are unique to tadalafil among PDE5 inhibitors 2. Cardiovascular screening is essential before prescribing any PDE5 inhibitor; the Princeton III Consensus recommends exercise tolerance testing for men in the intermediate cardiac risk category 12.

Alprostadil injection causes penile pain in roughly 37% of users (usually mild and self-limited), penile fibrosis or Peyronie's-like plaques in 2 to 12% with long-term use, and priapism in about 1% of treatment cycles 4. MUSE-specific adverse events include urethral pain/burning (33%), dizziness (4%), and minor urethral bleeding (5%) 6. There is no systemic cardiovascular contraindication for alprostadil; men on nitrates can safely use it, which is a key clinical advantage 13.

Ongoing monitoring for alprostadil users should include periodic palpation of the penis for fibrotic nodules every three to six months 7. If palpable plaques develop, the injection site should be rotated or therapy discontinued.

Cost and Access Considerations

Generic tadalafil became available in 2018 after the Cialis patent expired, reducing the average retail price to approximately $0.50 to $2.00 per 20 mg tablet at most US pharmacies. Daily tadalafil 5 mg ranges from $15 to $45 per month with a GoodRx-type coupon.

Alprostadil remains significantly more expensive. Brand Caverject Impulse costs $50 to $80 per single-use injection kit. MUSE pellets retail at roughly $35 to $60 per dose. Neither product has a widely available generic in the US, though compounding pharmacies can prepare alprostadil in multi-use vials at lower per-dose cost 17. Insurance coverage for alprostadil varies; many plans require documented PDE5 inhibitor failure before authorizing it.

This cost asymmetry means most men try tadalafil first for financial reasons alone, and only move to alprostadil after confirmed oral therapy failure.

Clinical Decision Framework for Switching

The decision tree is straightforward. Start with tadalafil (or another PDE5 inhibitor) per AUA first-line guidance 7. If the patient fails four to six adequate on-demand trials or cannot take PDE5 inhibitors due to nitrate use or other contraindications, transition to alprostadil. Choose Caverject injection for maximal efficacy or MUSE if the patient refuses needle-based therapy. Reserve combination therapy for partial responders willing to accept heightened priapism risk under physician oversight.

For men already on alprostadil, re-challenge with tadalafil when the clinical picture changes: nitrate therapy stops, nerve function returns post-surgery, or fibrosis makes continued injection impractical. The re-challenge dose should start at 10 mg on demand, escalating as needed 3.

Tadalafil 5 mg daily provides the unique dual benefit of ED and BPH symptom relief in men over 45 with both conditions, a factor that may tip the switching decision toward oral therapy when feasible 3.